Interview with Worwick Anderson, NHMRC,
Would you begin by outlining the key milestones & achievements of the NHMRC in the past four years? The first point is the development of our initiatives on an international…
Address: Level 1, 16 Marcus Clarke Street, Canberra,Australia
Tel: +61 2 6217 9000
The NHMRC is Australia’s NIH equivalent, being the big government funding body for health and medical research. We have always had in our portfolio a full range of health and medical research. Some funding bodies like the UKMRC are more biomedical, but the NHMRC has always been concerned with public health and health services research, so it’s a very broad portfolio. The NHMRC is more than a funding body, and strives to improve the lives of all Australians. For example, the organization publishes evidence-based guidelines for clinical practice and public health. An example of the latter is the current work being completed in finalizing safe alcohol-drinking guidelines, around which there is some controversy as we speak, because the message from science and what the public would like to believe do not always align.
The NHMRC also manages research and clinical ethics systems for Australia, publishing guidelines in this regard. Overall, it’s a fantastic organization of great importance to the health and wealth of the country. The NHMRC was a part of the Department of Health until July of 2006, when, coinciding with my arrival, we became an independent government body within the health portfolio, reporting directly to the Minister, which gives us all sorts of opportunities. Other aspects of the NHMRC portfolio include acting as the body under the Australian parliament act around stem cells, to issue licensing for cloning and embryo experimentation.
Would you begin by outlining the key milestones & achievements of the NHMRC in the past four years? The first point is the development of our initiatives on an international…
Your distinguished career in health research leadership and management has seen you through a variety of prestigious positions, not to mention the Order of Australia. Most recently you were appointed…
Australia will shortly have its latest national election, and we are again seeing pharmaceuticals being front and centre in the campaign. The starter’s gun has been fired for the…
A whistlestop tour though the latest news from pharma in Asia, taking in the American gene sequencing giant caught in the crosshairs of the US-China tariff row, the ADC-focused Singaporean…
Regular contributor Brendan Shaw looks ahead to a potentially turbulent 2025 for the pharmaceutical industry, highlighting five key trends that industry stakeholders must carefully navigate over the coming 12 months.…
In his latest opinion piece, Shawview Consulting’s Brendan Shaw draws from classic sci-fi to reflect on the pros and cons of using artificial intelligence for health technology assessment. Shaw concludes…
Richard Day of the University of New South Wales, writing in the October 2023 edition of DIA’s Global Forum magazine, looks at updates to the health technology assessment (HTA) processes…
Shawview Consulting’s Brendan Shaw looks back on a sombre United Nations High Level Meeting on Universal Health Coverage in New York last month, as stakeholders reflected on the long road…
After last year’s acquisition of Vifor Pharma, the firm’s largest ever, opened new avenues for diversification, the ground-breaking approval of the Hemgenix gene therapy for Hemophilia B was an equally…
Shawview Consulting’s Brendan Shaw casts his eye over the increased industry focus on Environment, Social, and Governance (ESG) issues in recent years, urging pharma companies to deliver on their ESG promises…
Brendan Shaw looks ahead to the rest of 2023, identifying five key trends to watch out for in the healthcare and life sciences sector. With the worst of COVID-19 now…
CSL, Australia’s largest biopharma company, overcame the challenges of the pandemic-related decline in plasma collection and has since racked up wins such as the acquisition of Vifor, the largest in…
A roundup of some of the latest news from Australian pharma, including CSL’s unification of business units, a workers strike at Pfizer’s manufacturing plant, a new USD 173 million research…
Pharmaceutical policy issues played a major role in Australia’s recent national election. Shawview Consulting’s Brendan Shaw outlines the medicines issues that came under scrutiny during the campaign. It was the…
See our Cookie Privacy Policy Here
